^
Association details:
Biomarker:FLT3 D835Y
Cancer:Acute Myelogenous Leukemia
Drug:BGS-2456 (FLT3 inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Source:
Title:

2265 BGS-2456 Is a Novel Potent Covalent Inhibitor of FLT3 That Highly Discriminates Against KIT and Is Not Toxic Toward Normal Hematopoiesis in Vitro

Published date:
11/02/2023
Excerpt:
...we assessed BGS-2456’s ability to retain activity against the known clinically problematic drug-resistant FLT3-ITD mutants D835Y and F691L. Encouragingly, BGS-2456 retained activity against both D835Y and F691L mutants in the low nanomolar range.